Recordati SpA
REC
Company Profile
Business description
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
Contact
Via Matteo Civitali 1
MIlan20148
ITAT: +39 2487871
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
4,693
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,223.93 | 315.19 | 3.99% |
| DAX 40 | 23,993.38 | 1,071.79 | 4.68% |
| Dow JONES (US) | 46,584.46 | 85.42 | -0.18% |
| FTSE 100 | 10,588.71 | 239.92 | 2.32% |
| HKSE | 25,845.24 | 728.71 | 2.90% |
| NASDAQ | 22,017.85 | 21.51 | 0.10% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,616.85 | 5.02 | 0.08% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |